Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 - PubMed (original) (raw)
. 2010 Jul 22;466(7305):451-6.
doi: 10.1038/nature09291.
Alexander S Banks, Jennifer L Estall, Shingo Kajimura, Pontus Boström, Dina Laznik, Jorge L Ruas, Michael J Chalmers, Theodore M Kamenecka, Matthias Blüher, Patrick R Griffin, Bruce M Spiegelman
Affiliations
- PMID: 20651683
- PMCID: PMC2987584
- DOI: 10.1038/nature09291
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5
Jang Hyun Choi et al. Nature. 2010.
Abstract
Obesity induced in mice by high-fat feeding activates the protein kinase Cdk5 (cyclin-dependent kinase 5) in adipose tissues. This results in phosphorylation of the nuclear receptor PPARgamma (peroxisome proliferator-activated receptor gamma), a dominant regulator of adipogenesis and fat cell gene expression, at serine 273. This modification of PPARgamma does not alter its adipogenic capacity, but leads to dysregulation of a large number of genes whose expression is altered in obesity, including a reduction in the expression of the insulin-sensitizing adipokine, adiponectin. The phosphorylation of PPARgamma by Cdk5 is blocked by anti-diabetic PPARgamma ligands, such as rosiglitazone and MRL24. This inhibition works both in vivo and in vitro, and is completely independent of classical receptor transcriptional agonism. Similarly, inhibition of PPARgamma phosphorylation in obese patients by rosiglitazone is very tightly associated with the anti-diabetic effects of this drug. All these findings strongly suggest that Cdk5-mediated phosphorylation of PPARgamma may be involved in the pathogenesis of insulin-resistance, and present an opportunity for development of an improved generation of anti-diabetic drugs through PPARgamma.
Conflict of interest statement
Conflicting interests statement. The authors declare that they have no competing financial interests.
Figures
Figure 1. Specific fat cell gene dysregulation by the cdk5-mediated S273 phosphorylation of PPARγ
a, In vitro CDK assays performed using cdk5/p35 with either wild type (WT) or S273A mutated PPARγ. b, Phosphorylation of PPARγ in differentiated 3T3-L1 adipocytes stimulated with TNF-α for the indicated times. c, Phosphorylation of PPARγ in cells expressing scrambled or CDK5 shRNA stimulated with indicated cytokines. NT, no treatment. d, Staining of PPARγ-null fibroblasts expressing WT or S273A mutant PPARγ with Oil-Red-O. e, Gene expression in these cells was analyzed by real-time quantitative PCR (qPCR) for expression of various genes (n=3). f, mRNA expression in transplanted fat pads was analyzed by qPCR (n=5) (Error bars are s.e.m.; *p<0.05, **p<0.01).
Figure 2. CDK5-mediated phosphorylation of PPARγ is increased in fat tissues of high fat diet fed mice (HFD)
a, White adipose tissue (epididymal) from mice on HFD for the indicated time was analyzed with phospho-S273 PPARγ and PPARγ antibodies. b, Epididymal (Epi.) or inguinal (Ing.) fat tissue from 13 weeks HFD mice was analyzed with phospho-S273 antibody.
Figure 3. Anti-diabetic PPARγ ligands block CDK5-mediated phosphorylation of PPARγ
a, TNF-α-induced phosphorylation of PPARγ in 3T3-L1 adipocytes expressing either WT or Q286P mutant of PPARγ treated with rosiglitazone and/or GW9662. b and c, In vitro CDK5 assay with either rosiglitazone or MRL24. d, Transcriptional activity of a PPAR-derived reporter gene in response to rosiglitazone or MRL24 (n=3). e, Microarray analysis of differentiated PPARγ-null fibroblasts expressing WT (NT, rosiglitazone or MRL24 treated) or S273A mutant PPARγ. f, mRNA expression of genes regulated by the phosphorylation of PPARγ in epididymal fat tissue of mice on either chow or HFD for 13 weeks (n=5). Error bars are s.e.m.; *p<0.05, **p<0.01, ***p<0.001.
Figure 4. Differential HDX MS data for PPARγ-LBD ± rosiglitazone and MRL24
a, Histograms showing the percent reduction in HDX for Helix 3 (IRIFQGCQF), the β-sheet region (ISEGQGFMTRE), Helix 12 (QEIYKDLY) and the Helix 2-2’ link region containing the site of CDK5 phosphorylation (KTTDKSPFVIYDM). Values are calculated relative to the measured %D value for apo PPARγ-LBD (n=4; error bars are s.e.m.; **p<0.01, ***p<0.001). b, HDX data for the four peptides of interest are plotted over the structures of PPARγ-LBD bound with rosiglitazone (left, PDB:2PRG) and MRL24 (right, PDB:2Q5P). Percent reduction in HDX relative to unliganded receptor is colored according to the key. Red circle indicates Ser273 residue of PPARγ.
Figure 5. Correlation between the inhibition of phosphorylation and improvement of insulin sensitivity by anti-diabetic PPARγ ligands
a, Glucose-tolerance tests in 16-week HFD mice treated with vehicle, rosiglitazone or MRL24 (n=10). b, phosphorylation of PPARγ in WAT. c, The expression of gene sets regulated by PPARγ phosphorylation in WAT (Error bars are s.e.m.; *p<0.05, **p<0.01, ***p<0.001). d, Changes of phosphorylation of PPARγ in human fat biopsies which were treated with rosiglitazone for 6 months. before, non-treated; after, 6 months treatment. e, Correlation between the changes of PPARγ phosphorylation normalized to total PPARγ protein and the changes of glucose infusion rate measured by clamp. The data is presented as percent change after 6 months of rosiglitazone treatment.
Comment in
- Obesity: New life for antidiabetic drugs.
Houtkooper RH, Auwerx J. Houtkooper RH, et al. Nature. 2010 Jul 22;466(7305):443-4. doi: 10.1038/466443a. Nature. 2010. PMID: 20651677 Free PMC article.
Similar articles
- Obesity: New life for antidiabetic drugs.
Houtkooper RH, Auwerx J. Houtkooper RH, et al. Nature. 2010 Jul 22;466(7305):443-4. doi: 10.1038/466443a. Nature. 2010. PMID: 20651677 Free PMC article. - Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schürer SC, Vidović D, Shulman GI, Spiegelman BM, Griffin PR. Choi JH, et al. Nature. 2011 Sep 4;477(7365):477-81. doi: 10.1038/nature10383. Nature. 2011. PMID: 21892191 Free PMC article. - GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA, Rajagopalan S, Lin JZ, Carvalho BM, Figueira AC, Lu J, Ayers SD, Mottin M, Silveira RL, Souza PC, Mourão RH, Saad MJ, Togashi M, Simeoni LA, Abdalla DS, Skaf MS, Polikparpov I, Lima MC, Galdino SL, Brennan RG, Baxter JD, Pitta IR, Webb P, Phillips KJ, Neves FA. Amato AA, et al. J Biol Chem. 2012 Aug 10;287(33):28169-79. doi: 10.1074/jbc.M111.332106. Epub 2012 May 14. J Biol Chem. 2012. PMID: 22584573 Free PMC article. - Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ.
Floyd ZE, Stephens JM. Floyd ZE, et al. Biochim Biophys Acta. 2012 Jul;1822(7):1090-5. doi: 10.1016/j.bbadis.2012.03.014. Epub 2012 Apr 4. Biochim Biophys Acta. 2012. PMID: 22504298 Free PMC article. Review. - Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
Whitehead JP. Whitehead JP. Int J Biochem Cell Biol. 2011 Aug;43(8):1071-4. doi: 10.1016/j.biocel.2011.04.017. Epub 2011 May 5. Int J Biochem Cell Biol. 2011. PMID: 21558015 Review.
Cited by
- Amphiphilic cytokine traps remodel marrow adipose tissue for hematopoietic microenvironment amelioration.
Deng S, Zhang S, Shen T, Wang X, Gao Z, Zhang W, Dai K, Wang J, Liu C. Deng S, et al. Bioact Mater. 2024 Sep 3;42:226-240. doi: 10.1016/j.bioactmat.2024.08.032. eCollection 2024 Dec. Bioact Mater. 2024. PMID: 39285915 Free PMC article. - Glucose-Dependent Insulinotropic Polypeptide Inhibits AGE-Induced NADPH Oxidase-Derived Oxidative Stress Generation and Foam Cell Formation in Macrophages Partly via AMPK Activation.
Terasaki M, Yashima H, Mori Y, Saito T, Inoue N, Matsui T, Osaka N, Fujikawa T, Ohara M, Yamagishi SI. Terasaki M, et al. Int J Mol Sci. 2024 Sep 8;25(17):9724. doi: 10.3390/ijms25179724. Int J Mol Sci. 2024. PMID: 39273671 Free PMC article. - Lipid synthesis, triggered by PPARγ T166 dephosphorylation, sustains reparative function of macrophages during tissue repair.
Zuo S, Wang Y, Bao H, Zhang Z, Yang N, Jia M, Zhang Q, Jian A, Ji R, Zhang L, Lu Y, Huang Y, Shen P. Zuo S, et al. Nat Commun. 2024 Aug 23;15(1):7269. doi: 10.1038/s41467-024-51736-5. Nat Commun. 2024. PMID: 39179603 Free PMC article. - A tethering mechanism underlies Pin1-catalyzed proline cis-trans isomerization at a noncanonical site.
Williams CC, Chuck J, Munoz-Tello P, Kojetin DJ. Williams CC, et al. bioRxiv [Preprint]. 2024 Jul 23:2024.07.19.604348. doi: 10.1101/2024.07.19.604348. bioRxiv. 2024. PMID: 39091828 Free PMC article. Preprint. - Gingival Enlargement Associated with Orthodontics Appliance Increases Protein Carbonylation and Alters Phosphorylation of Salivary Proteome.
Lopez Arrieta Z, Rodríguez-Cavallo E, Méndez-Cuadro D. Lopez Arrieta Z, et al. Dent J (Basel). 2024 Jul 8;12(7):208. doi: 10.3390/dj12070208. Dent J (Basel). 2024. PMID: 39056995 Free PMC article.
References
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004;89:2548–2556. - PubMed
- Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91. - PubMed
- Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia. 2006;49:2162–2173. - PubMed
- Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312. - PubMed
- Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001;7:947–953. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U54 MH084512/MH/NIMH NIH HHS/United States
- K99 DK087853/DK/NIDDK NIH HHS/United States
- U54 MH084512-020010/MH/NIMH NIH HHS/United States
- R01 GM084041-03/GM/NIGMS NIH HHS/United States
- DK31405/DK/NIDDK NIH HHS/United States
- R37 DK031405-30/DK/NIDDK NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- R37 DK031405/DK/NIDDK NIH HHS/United States
- R01 DK031405/DK/NIDDK NIH HHS/United States
- R01 GM084041/GM/NIGMS NIH HHS/United States
- U54-MH084512/MH/NIMH NIH HHS/United States
- DK087853/DK/NIDDK NIH HHS/United States
- R00 DK087853/DK/NIDDK NIH HHS/United States
- S10 RR027270/RR/NCRR NIH HHS/United States
- R01-GM084041/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases